CytomX Therapeutics Inc. Common Stock (CTMX)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earnings and a margin of safety, and CytomX does not currently fit that mold. It is an oncology-focused biotech platform with 69 employees. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $1.4M and a net loss of $20.7M. That followed fiscal Q1 2026, ended 2026-03-31, with revenue of $10.3M and a net loss of $18.2M. The annual picture is volatile: FY2024, ended 2024-12-31, had revenue of $138.1M and net income of $31.9M, but FY2025, ended 2025-12-31, had revenue of $76.2M and a net loss of $17.4M. A durable moat is hard to identify from these figures; revenue is lumpy, and there is no steady earnings stream. Financial health is weak: trailing free cash flow is -$82.5M, a FairStock-calculated FCF yield of -16.3%; FairStock-calculated Piotroski is 1/9 and Altman is 1.93. The debt-to-equity of 0.02 is a positive, but it does not offset the cash burn. Valuation is not cheap on earnings: at the close on 2026-10-13, price was $2.33 and market cap $506.6M, with FairStock-calculated P/E -4.08, P/B 1.67, ROE -37.75%, ROCE -19.58%, and FairStock score 21/100. Peter Lynch category is TURNAROUND — Loss in latest year after earlier profits. I would want evidence of durable revenue and self-funding before treating this as a bargain.

In plain English: CytomX is a small biotech company working on cancer treatments. The business looks weak right now: revenue dropped sharply, it is losing money, and it burns cash. At $2.33 on 2026-10-13, the price does not look cheap based on current sales and losses; it looks more like a bet on future drug progress than a steady business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer